The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Echo IQ (EIQ) releases EchoSolv, its cloud-based enhanced screening platform for structural heart disease, in the US
  • EchoSolv has been developed and “rigorously tested” in consultation with leading cardiologists, the company says
  • The product is designed to support clinicians and physicians in identifying patients with guideline-defined aortic stenosis
  • Chief Commercial Officer Deon Strydom says the launch is an important step in the US and the company is looking to deploying at several leading hospitals and health systems
  • Shares in Echo IQ closed at 19 cents on Wednesday afternoon

Echo IQ (EIQ) has released EchoSolv, its cloud-based enhanced screening platform for structural heart disease, in the US.

The company said EchoSolv had been developed and “rigorously tested” in consultation with leading cardiologists.

It is designed to support clinicians and physicians in identifying patients with guideline-defined aortic stenosis, which is one of the most common and serious types of heart valve disease.

The product has achieved positive results in a clinical effectiveness and validation study at the Beth Israel Deaconess Medical Centre within the Harvard Medical School.

The study demonstrated the platform could identify sizeable cohorts of patients with guideline-detected severe aortic stenosis as well as those with a significantly heightened risk of death from the condition.

Echo IQ Chief Commercial Officer Deon Strydom said the launch was an important step for the company in the US.

“Our experienced and highly-regarded healthcare executive, Don Fowler, is already engaging with several leading hospitals, ASCs and health systems in leading US cardiology markets from his base in Austin, Texas, and we expect to be seeing EchoSolv deployed with a number of these at pace,” he said.

“Looking further ahead, we look forward to incorporating new features, capabilities, and additional conditions beyond aortic stenosis into EchoSolv — many of which are currently in development.”

Echo IQ said EchoSolv would be available in two pricing models — a “price-per-assessment” model and a flat monthly software-as-a-service (SaaS) fee.

The former will allow customers to conduct retrospective patient reviews and be charged for any records which are evaluated using the platform.

The latter is for customers integrating EchoSolv into their real-time clinical workflows for immediate patient assessments.

The platform enables bulk assessments to be completed at a rate of up to 48,000 per minute.

The results can be exported into formats including PDF and clinicians can opt to send text or email alerts to high-risk patients.

Shares in Echo IQ closed at 19 cents on Wednesday afternoon.

EIQ by the numbers
More From The Market Online
The Market Online Video

Daily ASX Market Close: Index slides as basketball fan makes $40 million bid for Perth Wildcats, May 30, 2024

The ASX200 continued to slide today, shedding another half a per cent off the back of…
The Market Online Video

Daily ASX Market Update: Materials drags market under – May 30, 2024

The ASX200 is trading down as predicted, around half a per cent.

Sports Entertainment Group jumps 15% as firm bids to buy Perth Wildcats for $40M

Sports Entertainment Group announced on Thursday it has received a non-binding offer to buy WA basketball…
The Market Online Video

Market Update: ASX turns green with real estate flowering

The ASX200 is trading up around 0.7 per cent.